Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) Short Interest Up 20.9% in February

Evaxion A/S – Sponsored ADR (NASDAQ:EVAX) was the recipient of a significant growth in short interest in the month of February. As of February 13th, there was short interest totaling 82,140 shares, a growth of 20.9% from the January 29th total of 67,935 shares. Based on an average trading volume of 51,786 shares, the days-to-cover ratio is currently 1.6 days. Currently, 1.7% of the shares of the company are short sold. Currently, 1.7% of the shares of the company are short sold. Based on an average trading volume of 51,786 shares, the days-to-cover ratio is currently 1.6 days.

Evaxion A/S Trading Up 9.3%

EVAX opened at $3.40 on Friday. The firm’s 50 day simple moving average is $3.94 and its two-hundred day simple moving average is $4.61. The company has a market capitalization of $28.36 million, a PE ratio of -8.72 and a beta of 0.28. Evaxion A/S has a 1-year low of $1.20 and a 1-year high of $12.15.

Evaxion A/S (NASDAQ:EVAX) last announced its earnings results on Thursday, March 5th. The company reported $0.30 EPS for the quarter. Equities analysts forecast that Evaxion A/S will post -0.15 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

EVAX has been the topic of several research reports. Maxim Group started coverage on shares of Evaxion A/S in a report on Thursday, February 19th. They issued a “buy” rating and a $10.00 target price on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Evaxion A/S in a report on Friday, January 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $11.75.

Institutional Investors Weigh In On Evaxion A/S

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Northwestern Mutual Wealth Management Co. bought a new stake in Evaxion A/S during the 4th quarter worth approximately $38,000. Wesbanco Bank Inc. purchased a new stake in shares of Evaxion A/S in the fourth quarter worth $48,000. Finally, SmartHarvest Portfolios LLC bought a new stake in shares of Evaxion A/S during the 4th quarter valued at $72,000. 11.04% of the stock is owned by hedge funds and other institutional investors.

Evaxion A/S Company Profile

Evaxion A/S is a clinical-stage biotechnology company headquartered in Copenhagen, Denmark, with additional operations in the United States. The company specializes in the development of immunotherapies and vaccines driven by its proprietary AI-based computational immunology platform. By leveraging machine learning and deep learning algorithms, Evaxion identifies and optimizes antigen targets for both therapeutic cancer vaccines and prophylactic vaccines against infectious diseases.

At the core of Evaxion’s business is its AI platform, which analyzes large datasets of genomic, proteomic and immunological information to predict immune-stimulating epitopes.